Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-413 in Speech-in-noise Hearing Impairment
NCT04129775Phase 2Completed
- Sponsor
- Otonomy, Inc.
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of OTO-413 in sensorineural hearing loss (SNHL), sponsored by Otonomy, Inc.. Started Oct 2019; status: completed.
02
Drugs
OTO-413
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT04129775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129775.